Literature DB >> 15837115

The global alliance for tuberculosis drug development--accomplishments and future directions.

Charles A Gardner1, Tara Acharya, Ariel Pablos-Méndez.   

Abstract

The Global Alliance for Tuberculosis Drug Development (TB Alliance) aims to stop the spread of tuberculosis by developing new, faster-acting, and affordable tuberculosis drugs. The TB Alliance is a public-private partnership, a not-for-profit enterprise, that draws upon the resources of both private and public institutions to help address this urgent health need. This article summarizes some of the achievements of the TB Alliance to date and outlines potential future directions.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15837115     DOI： 10.1016/j.ccm.2005.02.008

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN： 0272-5231            Impact factor:   2.878


  8 in total

1.  Strong in vitro activities of two new rifabutin analogs against multidrug-resistant Mycobacterium tuberculosis.

Authors:  Ana-Belén García; Juan J Palacios; María-Jesús Ruiz; José Barluenga; Fernando Aznar; María-Paz Cabal; José María García; Natalia Díaz
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

Review 2.  New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

Authors:  Jossy van den Boogaard; Gibson S Kibiki; Elton R Kisanga; Martin J Boeree; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

3.  Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.

Authors:  Ciaran Skerry; Michael L Pinn; Natalie Bruiners; Richard Pine; Maria L Gennaro; Petros C Karakousis
Journal:  J Antimicrob Chemother       Date:  2014-05-22       Impact factor: 5.790

Review 4.  New drugs and regimens for treatment of TB.

Authors:  Eric Leibert; William N Rom
Journal:  Expert Rev Anti Infect Ther       Date:  2010-07       Impact factor: 5.091

Review 5.  Antituberculosis therapy for 2012 and beyond.

Authors:  Michael Lauzardo; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2012-02-15       Impact factor: 3.889

Review 6.  Innovative payer engagement strategies: will the convergence lead to better value creation in personalized medicine?

Authors:  Ildar Akhmetov; Rostyslav V Bubnov
Journal:  EPMA J       Date:  2017-02-13       Impact factor: 6.543

7.  Factors associated with the rapid implementation process of the fixed-dose combination RHZE tuberculosis regimen in Brazil: an ecological study.

Authors:  José Ueleres Braga; Deborah Araújo da Conceição; Anete Trajman
Journal:  BMC Public Health       Date:  2013-04-09       Impact factor: 3.295

Review 8.  Determining quantitative targets for public funding of tuberculosis research and development.

Authors:  David R Walwyn
Journal:  Health Res Policy Syst       Date:  2013-03-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.